AgiBot develops and manufactures humanoid robots and embodied intelligence systems designed for various applications, including interactive services and flexible manufacturing. Their technology enhances productivity by automating tasks in diverse environments, addressing labor shortages and operational inefficiencies.

Kai is an AI-powered reservations agent that automates guest inquiries across multiple platforms, including websites and social media, providing instant responses in over 50 languages. By streamlining communication and reducing response times, Kai increases direct bookings for hotels while allowing staff to focus on higher-priority tasks.

This startup offers an online platform that empowers women and LGBTQ artists to launch and manage NFT initiatives, utilizing decentralized finance tools to enhance visibility and access to resources. By fostering a community-driven ecosystem, the platform addresses the lack of equitable opportunities in the crypto space for underrepresented creators.

Westlake Omics develops AI-powered proteomics technology that enhances the precision of tumor diagnostics through quantitative and spatial proteomics methods. By providing reliable diagnostic tools, the company aims to improve patient outcomes in clinical settings by enabling accurate tumor characterization.

Shanghai-based Fintech company FuShu specializes in providing data-driven financial solutions that enhance transaction transparency and security for businesses. By utilizing advanced analytics and blockchain technology, FuShu addresses the challenges of fraud and inefficiency in financial operations.

Shargetech develops and manufactures gallium nitride (GaN) chargers that provide faster charging times and improved energy efficiency for consumer electronics. By utilizing GaN technology, these chargers reduce heat generation and size, addressing the demand for compact and high-performance charging solutions.

The startup develops TCR gene therapy solutions that provide personalized immunotherapy for cancer patients by engineering T-cell receptors to target specific tumor antigens. This approach enhances treatment efficacy and minimizes side effects compared to traditional therapies.